Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company’s products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; and CHC, which is used for the treatment of soft tissue injuries. The company was incorporated in 1991 and is based in Uppsala, Sweden.
Metrics to compare | CLBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCLBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −17.8x | −4.7x | −0.6x | |
PEG Ratio | 0.02 | −0.14 | 0.00 | |
Price/Book | 2.0x | 3.4x | 2.6x | |
Price / LTM Sales | 7.3x | 14.8x | 3.2x | |
Upside (Analyst Target) | 180.5% | 34.8% | 45.4% | |
Fair Value Upside | Unlock | −1.9% | 7.7% | Unlock |